The investigational medical device Traumacel FAM Trium is a sterile plant polysaccharide haemostatic agent based on the oxidized cellulose in the form of multilayer nonwoven fabric. It is used as an adjunct to stop capillary, venous, or small arterial bleeding, and also to prevent early postoperative bleeding. It can be used in all areas of stopping diffuse bleeding from resection surfaces such as parenchymatous organs, muscles or defined body cavities. The wide scope of application allows the use for classical, robotic surgery and endoscopic treatments (e.g. laparoscopic). The main objective of the study is to compare the efficacy and safety of Traumacel FAM Trium and regenerated oxidized cellulose based fibrous haemostat when used in accordance with their intended purpose. The partial objectives are: identification of any previously unknown side-effects and monitoring of known side-effects; identification and analysis of potentially newly emerging risks; confirmation of the acceptability of the benefit-risk ratio; identification of any systematic misuse of the device or off-label use of the device in order to verify the correctness of its intended purpose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
98
Absorbable Hemostat (oxidized non-regenerated cellulose)
Absorbable Hemostat (oxidized regenerated cellulose)
University Hospital Hradec Králové
Hradec Králové, Czechia
Time required to achieve haemostasis.
Time frame: 10 minutes
Number of subjects in whom haemostasis was achieved within 3 minutes after administration.
Time frame: 3 minutes
Number of subjects who required surgical revision within 12 hours after the procedure for recurrent bleeding.
Time frame: 12 hours
Number of subjects in whom haemostasis was achieved within 2 minutes after administration.
Time frame: 2 minutes
Degree of bleeding from target bleeding site
Time frame: 10 minutes
Number of subjects with complications during surgery.
Time frame: During a surgical procedure, an average of 1 hour
Occurrence of adverse events.
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.